Is This the Right Time to Add Resmed Stock to Your Portfolio?

ResMed is showing continued demand for its AirSense 10/11 platforms with global device sales up 9% in fiscal Q1 2026 (8% in U.S./Canada/Latin America; 11% in Europe/Asia/other) and combined regional sales up 10%. The company is expanding in high-growth markets (eg. AirSense 11 launched in India) while maintaining a strong liquidity position—$1.38bn cash vs $408.7m long-term debt and a 6.3% debt-to-capital ratio—despite SG&A rising 9.5% YoY. Zacks consensus for fiscal 2026 EPS is $10.84 (up 0.2% in 30 days) with revenues forecast at $5.58bn (+8.4% YoY); ResMed has beaten EPS estimates in each of the last four quarters (avg surprise 3.04%). Key near-term risks include macroeconomic pressures, supply-chain/tariff exposures and persistent inflation that could pressure margins.

Analysis

Market structure: ResMed (RMD) is a beneficiary of durable demand for CPAP devices (global device sales +9% and FY26 revenue consensus $5.58B, +8.4% YoY) and gains pricing/attach rates via digital platforms (AirSense 10/11). Competitors without similar digital-reimbursement traction or balance-sheet flexibility will cede share in high-growth EMs (China/India/Brazil); however reimbursement ceilings and local low-cost entrants cap long-term ASPs. The firm’s net-cash position (cash $1.38B vs long-term debt $408.7M; debt-to-cap 6.3%) reduces credit sensitivity, likely compressing RMD’s credit spreads vs peers if growth persists.

Risk assessment: Key tail risks are a sudden reimbursement cut in major markets, a concentrated supplier shock for electronic components, or geopolitical tariffs reducing margins; each could swing margins by 200–500bps within 6–12 months. Near-term (days–weeks) risk centers on guidance/quarterly beats around EPS $10.84 FY26; medium-term (3–12 months) on regulatory rollouts of AirSense11 and supply-chain cost pass-through; long-term (2–4 years) on market share erosion in EMs from local competitors. Hidden dependency: digital-reimbursement timing—if payors delay coverage by 6–18 months, EM revenue forecasts will undershoot.

Trade implications: Tactical core-long (size 2–3% portfolio) favored given durable demand and net cash; target +12–18% upside over 12 months if international rollouts accelerate and margins stabilize. Use defined-risk option structures: buy 9–12 month call spreads to cap premium (buy ATM, sell 20–30% OTM) and buy 3–6 month puts (protective hedge sized to 0.5–1% portfolio) around macro risk windows. Consider a pair trade long RMD vs short a high-multiple, lower-quality medtech (e.g., BTSG) over 6–12 months to capture relative mean reversion if cost pressures persist.

Contrarian angles: Consensus underprices RMD’s balance-sheet optionality—net cash enables tuck-in M&A or buybacks that could unlock EPS beyond organic growth (supporting a >10% re-rate). Conversely, the market may be underestimating SG&A inflation (SG&A +9.5% YoY) and supply-cost pass-through risk; if SG&A remains elevated and device ASPs compress, margins could fall 200–400bps, making current optimism premature. Historical parallel: durable-medical-device rollouts in EMs often take 12–36 months to scale reimbursement; expect uneven quarters, not linear upside.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in RMD (ticker: RMD) in the next 2–4 weeks; set a hard stop at -12% and a 12-month upside target of +15%–18% tied to international revenue acceleration and meeting/raising FY26 guidance (EPS $10.84).
• On a pullback of 8–12% from current levels, add to increase exposure to 4–6% portfolio weight—this is a tactical accumulation window given strong net-cash balance sheet (cash $1.38B) and downside protection versus high-leverage peers.
• Implement a defined-risk bullish options trade: buy a 9–12 month RMD call spread (buy near-the-money call, sell a strike 20–30% higher) sized to cost no more than 0.5%–1% of portfolio to capture upside from product rollouts while capping premium paid.
• Buy a protective hedge: purchase 3–6 month RMD puts 8–12% OTM sized to 0.5%–1% portfolio (or equivalently buy puts on a healthcare-device ETF) to guard against abrupt reimbursement or supply-chain shocks around near-term macro data/earnings.
• Relative-value pair trade (6–12 months): long RMD vs short BTSG (or another high-multiple, lower-balance-sheet medtech) sized 1–2% net exposure to exploit RMD’s quality premium and potential mean reversion in smaller peers if SG&A and component costs compress margins.